Skip to main content
. Author manuscript; available in PMC: 2015 Oct 15.
Published in final edited form as: Clin Cancer Res. 2014 Apr 1;20(20):5290–5301. doi: 10.1158/1078-0432.CCR-14-0514

Figure 2.

Figure 2

Impact of IDO inhibition and tryptophan catabolic enzyme expression in brain tumors. (A) Timeline illustrating when oral (through the drinking water) 1-MT (2mg/mL) and i.p.-injected TMZ was administered to mice after intracranial injection (ic.) of 4×105 GL261 cells. (B) Survival analysis represents mice that received the L- or D-stereoisomer of 1-MT, TMZ, or a combination of each 1-MT stereoisomer with TMZ (n = 6/group). *P < 0.05; **P < 0.01. (C) Representative Western blots and (D) relative quantitative analysis for IDO1, IDO2, TDO and chicken β-actin in GL261 cell-based glioma lysates isolated at 1 and 3 weeks post- ic. in WT, IDO−/− and Rag1−/− mice (n = 3/group). *P < 0.05; **P < 0.01.